{"protocolSection":{"identificationModule":{"nctId":"NCT06481306","orgStudyIdInfo":{"id":"CA230-1019"},"secondaryIdInfos":[{"id":"2023-510283-12","type":"OTHER","domain":"EU CTR"},{"id":"U1111-1301-6753","type":"OTHER","domain":"WHO"}],"organization":{"fullName":"Bristol-Myers Squibb","class":"INDUSTRY"},"briefTitle":"A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease","officialTitle":"A Phase 1/2a, First-in-human, Randomized, Double-blinded, Placebo-controlled, Dose-finding Study in Healthy Volunteers and Participants With Sickle Cell Disease to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, pH and Food Effect, and Preliminary Efficacy of BMS-986470"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-07-15","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2027-01-06","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-11-16","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-25","studyFirstSubmitQcDate":"2024-06-25","studyFirstPostDateStruct":{"date":"2024-07-01","type":"ESTIMATED"},"lastUpdateSubmitDate":"2024-06-25","lastUpdatePostDateStruct":{"date":"2024-07-01","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bristol-Myers Squibb","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease."},"conditionsModule":{"conditions":["Anemia, Sickle Cell","Healthy Volunteers"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":184,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Cohort A Part 1","type":"EXPERIMENTAL","interventionNames":["Drug: BMS-986470","Drug: Placebo"]},{"label":"Cohort A Part 2","type":"EXPERIMENTAL","interventionNames":["Drug: BMS-986470","Drug: Placebo"]},{"label":"Cohort A Part 3","type":"EXPERIMENTAL","interventionNames":["Drug: BMS-986470"]},{"label":"Cohort B Part 1","type":"EXPERIMENTAL","interventionNames":["Drug: BMS-986470","Drug: Placebo"]},{"label":"Cohort B Part 2","type":"EXPERIMENTAL","interventionNames":["Drug: BMS-986470"]}],"interventions":[{"type":"DRUG","name":"BMS-986470","description":"Specified dose on specified days","armGroupLabels":["Cohort A Part 1","Cohort A Part 2","Cohort A Part 3","Cohort B Part 1","Cohort B Part 2"]},{"type":"DRUG","name":"Placebo","description":"Specified dose on specified days","armGroupLabels":["Cohort A Part 1","Cohort A Part 2","Cohort B Part 1"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of participants with adverse events (AEs)","timeFrame":"Up to Day 154"},{"measure":"Number of participants with serious adverse events (SAEs)","timeFrame":"Up to Day 154"},{"measure":"Number of participants with AEs meeting protocol-defined Dose Limiting Toxicity (DLT) criteria","timeFrame":"Up to Day 154"},{"measure":"Number of participants with AEs leading to discontinuation","timeFrame":"Up to Day 154"},{"measure":"Number of deaths","timeFrame":"Up to Day 154"}],"secondaryOutcomes":[{"measure":"Maximum observed plasma concentration (Cmax)","description":"Cohort A Parts 1 and 2 and Cohort B Part 1","timeFrame":"Up to Day 28"},{"measure":"Area under the concentration-time curve (AUC)","description":"Cohort A Parts 1 and 2 and Cohort B Part 1","timeFrame":"Up to Day 28"},{"measure":"Time of maximum observed plasma concentration (Tmax)","description":"Cohort A Parts 1 and 2 and Cohort B Part 1","timeFrame":"Up to Day 28"},{"measure":"Dose proportionality of BMS-986470 for Cmax and AUC","description":"Assessed by using the slope of a statistical linear relationship between the ln-transformed PK parameters AUC and Cmax and the ln-transformed dose will be fitted by using power model","timeFrame":"Up to Day 28"},{"measure":"Change from baseline in total hemoglobin (Hb)","description":"Cohort A Part 2, Cohort B Parts 1 and 2","timeFrame":"Up to Day 154"},{"measure":"Change from baseline in total Hb fractions: adult Hb (HbA)","description":"Cohort A Part 2","timeFrame":"Up to Day 28"},{"measure":"Change from baseline in total Hb fractions: fetal Hb (HbF)","description":"Cohort A Part 2, Cohort B Parts 1 and 2","timeFrame":"Up to Day 154"},{"measure":"Change from baseline in total Hb fractions: sickle Hb (HbS)","description":"Cohort B","timeFrame":"Up to Day 154"},{"measure":"Change from baseline in markers of red blood cell (RBC) lysis: total Hb","description":"Cohort B","timeFrame":"Up to Day 154"},{"measure":"Change from baseline in markers of RBC lysis: aspartate aminotransferase (AST)","description":"Cohort B","timeFrame":"Up to Day 154"},{"measure":"Change from baseline in markers of RBC lysis: lactate dehydrogenase (LDH)","description":"Cohort B","timeFrame":"Up to Day 154"},{"measure":"Change from baseline in markers of RBC lysis: total bilirubin","description":"Cohort B","timeFrame":"Up to Day 154"},{"measure":"Change from baseline in markers of RBC lysis: indirect bilirubin","description":"Cohort B","timeFrame":"Up to Day 154"},{"measure":"Change from baseline in markers of RBC lysis: haptoglobin","description":"Cohort B","timeFrame":"Up to Day 154"},{"measure":"Change from baseline in markers of RBC lysis: absolute reticulocyte count","description":"Cohort B","timeFrame":"Up to Day 154"},{"measure":"Change from baseline in markers of RBC lysis: reticulocyte percentage of RBCs","description":"Cohort B","timeFrame":"Up to Day 154"},{"measure":"Change from baseline in markers of RBC lysis: absolute schistocyte count","description":"Cohort B","timeFrame":"Up to Day 154"},{"measure":"Change from baseline in markers of RBC lysis: schistocyte percentage of RBCs","description":"Cohort B","timeFrame":"Up to Day 154"},{"measure":"Number of participants achieving HbF ≥ 10%","description":"Cohort B","timeFrame":"Up to Day 154"},{"measure":"Number of participants achieving HbF ≥ 20%","description":"Cohort B","timeFrame":"Up to Day 154"},{"measure":"Number of participants achieving HbF ≥ 30%","description":"Cohort B","timeFrame":"Up to Day 154"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n- Cohort A.\n\ni) Healthy male and female (who are not of childbearing potential) participants, as determined by the investigator based on medical history and other determinations. Females not of childbearing potential must have been amenorrhoeic for at least 12 months without an alternative medical cause and have follicle-stimulating hormone (FSH) levels of at least 40 IU/L or have undergone a hysterectomy, bilateral oophorectomy, or bilateral salpingectomy.\n\nii) Body mass index (BMI) of 18.0 to 32.0 kg/m\\^2, inclusive. BMI = weight (kg)/ (height \\[m\\])\\^2 as measured at screening.\n\niii) No evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG, or clinical laboratory assessments beyond what is consistent with the target population.\n\n- Cohort B.\n\ni) Participants with a documented diagnosis of Sickle Cell Disease (SCD) with genotype HbSS, HbSβ0-thal, or HbSβ+-thal.\n\nii) Participants with ≥ 4 vaso-occlusive crises (VOCs) within the previous 12 months or ≥ 2 VOCs within the previous 6 months.\n\niii) Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\niv) Must have the following laboratory values:.\n\nA. Hemoglobin ≥ 5.5 and ≤ 12 g/dL (males) or ≥ 5.5 and ≤ 10.6 g/dL (females).\n\nB. Absolute neutrophil count ≥ 1500/μL.\n\nC. Platelet count ≥ 100 × 10\\^3/μL.\n\nD. Absolute reticulocyte count \\> 100 × 10\\^3/μL or \\> 50 × 10\\^3/μL if taking hydroxyurea.\n\nExclusion Criteria\n\n- Cohort A.\n\ni) Any significant medical condition or any condition that confounds the ability to interpret data from the study.\n\nii) Participant has any condition, including the presence of laboratory abnormalities, that places the participant at unacceptable risk if the participant was to participate in the study.\n\niii) Any major surgery or planned surgery (except GI surgery) within 12 weeks of the first study intervention administration.\n\n- Cohort B.\n\ni) Participants with any condition, including significant acute or chronic medical illness, active or uncontrolled infection, or the presence of laboratory abnormalities, that places participants at unacceptable risk if participating in this study.\n\nii) Participants with more than 6 severe VOCs defined as VOCs requiring ≥ 24 hours of hospital admission within 12 months prior to the first dose of study intervention or any VOC requiring ≥ 24 hours of hospital admission within 30 days prior to the first dose of study intervention.\n\niii) Participants with any episode of acute chest syndrome within the last 6 months prior to the first dose of study intervention.\n\niv) Creatinine clearance (CrCl) \\< 60 mL/min/1.72m2 using Chronic Kidney Disease Epidemiology (CKD-EPI) equation\n\n* Cohort A and B.\n\n  i) Participant is receiving regularly scheduled RBC or platelet transfusions or has received a RBC transfusion within 28 days and a platelet transfusion within 14 days prior to starting treatment with BMS-986470.\n* Other protocol-defined Inclusion/Exclusion criteria apply.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","role":"CONTACT","phone":"855-907-3286","email":"Clinical.Trials@bms.com"},{"name":"First line of the email MUST contain the NCT# and Site #.","role":"CONTACT"}],"overallOfficials":[{"name":"Bristol-Myers Squibb","affiliation":"Bristol-Myers Squibb","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Local Institution - 0001","city":"Lenexa","state":"Kansas","zip":"66219","country":"United States","contacts":[{"name":"Site 0001","role":"CONTACT"}],"geoPoint":{"lat":38.95362,"lon":-94.73357}}]},"referencesModule":{"seeAlsoLinks":[{"label":"BMS Clinical Trial Information","url":"https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html"},{"label":"BMS Clinical Trial Patient Recruiting","url":"https://www.BMSStudyConnect.com"},{"label":"FDA Safety Alerts and Recalls","url":"http://www.fda.gov/safety/medwatch"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria.\n\nAdditional information regarding Bristol Myer Squibb's data sharing policy and process can be found at:\n\nhttps://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html","infoTypes":["STUDY_PROTOCOL","SAP","CSR"],"timeFrame":"See Plan Description","accessCriteria":"See Plan Description","url":"https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000000755","term":"Anemia, Sickle Cell"}],"ancestors":[{"id":"D000000745","term":"Anemia, Hemolytic, Congenital"},{"id":"D000000743","term":"Anemia, Hemolytic"},{"id":"D000000740","term":"Anemia"},{"id":"D000006402","term":"Hematologic Diseases"},{"id":"D000006453","term":"Hemoglobinopathies"},{"id":"D000030342","term":"Genetic Diseases, Inborn"}],"browseLeaves":[{"id":"M4085","name":"Anemia, Sickle Cell","asFound":"Anemia, Sickle Cell","relevance":"HIGH"},{"id":"M4070","name":"Anemia","relevance":"LOW"},{"id":"M9547","name":"Hemolysis","relevance":"LOW"},{"id":"M4073","name":"Anemia, Hemolytic","relevance":"LOW"},{"id":"M4075","name":"Anemia, Hemolytic, Congenital","relevance":"LOW"},{"id":"M9490","name":"Hematologic Diseases","relevance":"LOW"},{"id":"M9539","name":"Hemoglobinopathies","relevance":"LOW"},{"id":"M23686","name":"Genetic Diseases, Inborn","relevance":"LOW"},{"id":"T5229","name":"Sickle Cell Anemia","asFound":"Anemia, Sickle Cell","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BC15","name":"Blood and Lymph Conditions"},{"abbrev":"BC16","name":"Diseases and Abnormalities at or Before Birth"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false}